Physician profile
Anitha Christopher
NPI 1467642397
$8,588.82
in general payments reported to CMS, 2019-2025
34 companies · $1,634 in 2025
The $1,634 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $640 · 2020: $863 · 2021: $1,339 · 2022: $1,037 · 2023: $1,948 · 2024: $1,127 · 2025: $1,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,509 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,508.82 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,269.07 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $2,012.58 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $521.39 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $502.71 | 2020-2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $442.15 | 2019-2025 | Dupixent |
| Amgen INC. | $378.14 | 2019-2024 | Tezspire |
| Genzyme Corporation | $368.94 | 2019-2025 | |
| Grifols USA, LLC | $290.01 | 2020-2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $278.29 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $190.70 | 2019-2020 | |
| United Therapeutics Corporation | $128.09 | 2019-2021 | |
| Axsome Therapeutics, INC. | $121.81 | 2023 | Sunosi |
| Mylan Specialty L.P. | $119.28 | 2021-2024 | Yupelri |
| Baxter Healthcare | $114.79 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Pulmonx Corporation | $105.69 | 2020-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $95.57 | 2023-2025 | Winrevair |
| Electromed, INC. | $64.06 | 2024-2025 | Smartvest |
| Verona Pharma, INC. | $59.36 | 2025 | Ohtuvayre |
| Ambu INC. | $56.55 | 2022-2024 | |
| Paratek Pharmaceuticals, INC. | $54.75 | 2021-2025 | Nuzyra |
| Nabriva Therapeutics, Plc | $54.63 | 2020-2022 | |
| Inogen, INC. | $54.32 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Viatris Specialty LLC | $51.52 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $42.87 | 2021 | |
| Ethicon INC. | $41.71 | 2022 | |
| Insmed, INC. | $32.37 | 2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $23.56 | 2019 | |
| Vifor Pharma, INC. | $19.65 | 2025 | Veltassa |
| E.R. Squibb & Sons, L.L.C. | $19.43 | 2024 | Eliquis |
| Resmed Corp | $18.66 | 2019 | |
| Pfizer INC. | $16.35 | 2025 | |
| Medtronic, INC. | $14.88 | 2021 | |
| Philips North America LLC | $13.52 | 2023 | |
| Circassia INC. | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anitha Christopher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.